Friday, 16 October 2026European Markets

LATECOERE Stock Over 31% Down In The Last 21 Sessions

Loading stream...

latecoere stocks, listed on the cac 40 and known for aerostructures and interconnection systems, experienced a sharp 31.22% decrease over 21 sessions - from eur0.19 to eur0.13. despite a small uptick of 0.12% to eur7,348.84 following an unexpected decrease during one of its sessions, their drop reflected a much more serious trend than previously anticipated.

latecoere s.a. overview

latecoere s.a. operates across europe, the us, africa and asia to produce and install aerostructure and interconnection system components for aircrafts in these markets. their diverse product offering includes doors, fuselages, wings and essential aircraft essentials as well as avionics racks and electronics.

financial status and volatility

latecoere of toulouse reported an earnings per share (eps) figure of eur-0.18, potentially raising investor trepidation. furthermore, latecoere stock price volatility showed significant fluctuations with average intraday variations being between 3.75% and 3.74% over the last week and month - suggesting bearish behavior on the stock market.

investor opportunities and risks

however, the last quarter's positive average intraday variation of 3.73% offers some hope for recovery. average volatility peaked at 5.74% last week and 6.588% each month until reaching its highest amplitude at 3.73% for quarter ending q4. substantial shifts in share prices pose both risks and opportunities to investors.

conclusion

latecoere's declining stock value signals investor uncertainty regarding its financial state but suggests an imminent turnaround. prospective investors should closely follow company performance and market trends, use comprehensive risk management techniques, and make well-informed investment decisions.

more news about latecoere (lat.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com